- Home
- TWG vs KALA Comparison
TWG vs KALA Comparison
Compare TWG & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWG
- KALA
- Stock Information
- Founded
- TWG 2009
- KALA 2009
- Country
- TWG Hong Kong
- KALA United States
- Employees
- TWG N/A
- KALA N/A
- Industry
- TWG
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- TWG
- KALA Health Care
- Exchange
- TWG NYSE
- KALA Nasdaq
- Market Cap
- TWG 7.4M
- KALA 26.2M
- IPO Year
- TWG 2024
- KALA 2017
- Fundamental
- Price
- TWG $0.14
- KALA $5.86
- Analyst Decision
- TWG
- KALA Strong Buy
- Analyst Count
- TWG 0
- KALA 3
- Target Price
- TWG N/A
- KALA $14.00
- AVG Volume (30 Days)
- TWG 8.7M
- KALA 118.3K
- Earning Date
- TWG 02-15-2025
- KALA 08-05-2025
- Dividend Yield
- TWG N/A
- KALA N/A
- EPS Growth
- TWG N/A
- KALA N/A
- EPS
- TWG N/A
- KALA N/A
- Revenue
- TWG $4,747,580.00
- KALA N/A
- Revenue This Year
- TWG N/A
- KALA N/A
- Revenue Next Year
- TWG N/A
- KALA N/A
- P/E Ratio
- TWG N/A
- KALA N/A
- Revenue Growth
- TWG N/A
- KALA N/A
- 52 Week Low
- TWG $0.10
- KALA $2.92
- 52 Week High
- TWG $13.50
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- TWG N/A
- KALA 60.68
- Support Level
- TWG N/A
- KALA $4.36
- Resistance Level
- TWG N/A
- KALA $7.00
- Average True Range (ATR)
- TWG 0.00
- KALA 0.71
- MACD
- TWG 0.00
- KALA 0.16
- Stochastic Oscillator
- TWG 0.00
- KALA 63.97
About TWG TOP WEALTH GROUP HLDG LTD
Top Wealth Group Holding Ltd is as supplier of caviar and offer caviar-based gourmet products. It is specialized in supplying high quality sturgeons caviar. Its mission is to become a world-renowned supplier of the finest selection of caviar and offer caviar-based gourmet products around the globe with an unparalleled gastronomical experience.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.